Patents by Inventor Nicholas J. Lawrence

Nicholas J. Lawrence has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • YAP1 inhibitors that target the interaction of YAP1 with OCT4
    Patent number: 10906874
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2, which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WAV domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit stemness. Disclosed are compounds that affect the Yap1:Oct4 interaction.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: February 2, 2021
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Srikumar Chellappan, Nicholas J. Lawrence, Sujeewa Ranatunga Mahanthe Mudiyanselage
  • BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20200407328
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 31, 2020
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells
    Patent number: 10813927
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: October 27, 2020
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Said M. Sebti, Nicholas J. Lawrence, James Turkson
  • BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10738016
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 11, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Potent dual BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10526291
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 7, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Gary W. Reuther
  • YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4
    Publication number: 20190375709
    Abstract: Binding of the transcriptional co-activator, YAP1, to the transcription factor Oct4, induces Sox2. which is a transcription actor necessary for the self-renewal of stem-like cells from non-small cell lung cancer. The WW domain of YAP1 binds to the PPxY motif of Oct4 to induce Sox2. Delivering a peptide corresponding to the WAV domain could prevent the induction of Sox2 and stemness. Similarly, peptides and mimetics of the PPxY motif would be able to inhibit stemness. Disclosed arc compounds that affect the Yap1:Oct4 interaction.
    Type: Application
    Filed: September 18, 2017
    Publication date: December 12, 2019
    Inventors: Srikumar CHELLAPAN, Nicholas J. LAWRENCE, Sujeewa Ranatunga Mahanthe MUDIYANSELAGE
  • Inhibitors of ACK1/TNK2 tyrosine kinase
    Patent number: 10336734
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: July 2, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20190055203
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • Potent dual BRD4-kinase inhibitors as cancer therapeutics
    Patent number: 10106507
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: October 23, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Insitute, Inc.
    Inventors: Ernst Shönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20180290984
    Abstract: Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
    Type: Application
    Filed: October 13, 2016
    Publication date: October 11, 2018
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence
  • PLATINUM COMPOUNDS THAT INHIBIT CONSTITUTIVE STAT3 SIGNALING AND INDUCE CELL CYCLE ARREST AND APOPTOSIS OF MALIGNANT CELLS
    Publication number: 20180256564
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 13, 2018
    Inventors: SAID M. SEBTI, NICHOLAS J. LAWRENCE, JAMES TURKSON
  • INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
    Publication number: 20180215738
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.
    Type: Application
    Filed: August 2, 2016
    Publication date: August 2, 2018
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • Inhibitors of ACK1/TNK2 tyrosine kinase
    Patent number: 10017478
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: July 10, 2018
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • INHIBITORS OF ACK1/TNK2 TYROSINE KINASE
    Publication number: 20180155297
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
    Type: Application
    Filed: November 9, 2017
    Publication date: June 7, 2018
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells
    Patent number: 9968599
    Abstract: The subject invention concerns a compound and compositions having activity as an inhibitor of Stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula I, formula II, or formula III. The subject invention also concerns methods of using the compounds and compositions of the invention.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: May 15, 2018
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Said M. Sebti, Nicholas J. Lawrence, James Turkson
  • Inhibitors of ACK1/TNK2 tyrosine kinase
    Patent number: 9850216
    Abstract: Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of Ack1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new Ack1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I through IV are disclosed.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 26, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Nupam P. Mahajan, Kiran N. Mahajan, Nicholas J. Lawrence, Harshani R. Lawrence
  • POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
    Publication number: 20170226065
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Application
    Filed: August 3, 2015
    Publication date: August 10, 2017
    Inventors: Ernst SHÖNBRUNN, Nicholas J. LAWRENCE, Harshani R. LAWRENCE
  • Thiosemicarbazones inhibitors of lysophosphatidic acid acyltransferase and uses thereof
    Patent number: 9622993
    Abstract: Lysophosphatidic acid acyltransferase-beta (LPAAT-?) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-?. LPAAT-? expression is a prognostic factor in gynecologic malignancies and is being investigated as a therapeutic target in a variety of tumor types. A class of thiosemicarbazones was identified as inhibitors of LPAAT-? from a screen of a library of small molecules. A focused library of thiosemicarbazones derivatives was prepared and led to the development of compounds which potently inhibit LPAAT-? and inhibit the growth of MiaPaCa2 human pancreatic cancer cells.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: April 18, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Gregory Springett, Said M. Sebti, Nicholas J. Lawrence
  • Rho kinase inhibitors and methods of use
    Patent number: 9616064
    Abstract: The subject invention concerns materials and methods for treating diseases and disorders associated with expression of Rho associated kinases (ROCKs). Examples of diseases and disorders contemplated within the scope of the invention include, but are not limited to, oncological disorders, cardiovascular diseases, CNS disorders, and inflammatory disorders. In one embodiment, a method of the invention comprises administering a therapeutically effective amount of one or more compounds of the present invention, or a composition comprising the compounds, to a person or animal in need of treatment. The subject invention also concerns compounds that inhibit ROCKs, and compositions that comprise the inhibitor compounds of the invention. Compounds contemplated within the scope of the invention include, but are not limited to, those compounds shown in Table 5.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: April 11, 2017
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Nicholas J. Lawrence, Said M. Sebti, Roberta Pireddu
  • Aurora kinase inhibitors and methods of making and using thereof
    Patent number: 9597329
    Abstract: Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: March 21, 2017
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc
    Inventors: Said M. Sebti, Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Matthew P. Martin